BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TMC435: Additional Phase IIb data

Interim 24-week data from the double-blind Phase IIb ASPIRE (C206) trial in 462 treatment-experienced patients with HCV genotype 1 infection showed that a significantly greater proportion of patients receiving once-daily 100 mg TMC435 for 12, 24 or 48 weeks plus standard of care (SOC; Pegasys peginterferon alfa-2a and Copegus ribavirin) achieved an RVR, defined as undetectable HCV RNA levels (<25 IU/mL) at week 4, vs. placebo plus SOC (67.7%, 59.4% and 53.8%, respectively, vs. 1.5%; p<0.001 for all). Additionally,...

Read the full 392 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >